AstraZeneca Defends Crestor; Public Citizen Renews Call For Withdrawal
Executive Summary
The post-marketing safety profile of Crestor is in line with the overall experience of the statin category, AstraZeneca said May 19 in response to a renewed request from Public Citizen for withdrawal of the cholesterol-lowering drug
You may also be interested in...
AERS Database Cannot Determine Adverse Event Incidence, FDA Says In Rejecting Statin Label Warning
FDA denies Public Citizen’s 2001 petition requesting a black box warning about the risk of rhabdomyolysis on cholesterol-lowering drug labels, says Baycol and high-dose simvastatin are outliers.
To Crestor’s Foe, FDA Says Toxicity Is Low, But DTC Ads Must Go
FDA says AstraZeneca's Crestor is as safe as, if not safer than, other statins for a given LDL-lowering efficacy, but its ad campaign cannot claim superiority to Pfizer's Lipitor
To Crestor’s Foe, FDA Says Toxicity Is Low, But DTC Ads Must Go
FDA says AstraZeneca's Crestor is as safe as, if not safer than, other statins for a given LDL-lowering efficacy, but its ad campaign cannot claim superiority to Pfizer's Lipitor